FDA Confirms Paragraph IV Patent Litigation for Lactic Acid, Citric Acid and Potassium Bitartrate
Evofem Biosciences announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,439,610, which covers the composition of matter of Phexxi (lactic acid, citric acid, potassium bitartrate).
SAN DIEGO, Sept. 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCPK: EVFM) today announced another new insurance win that gives millions of additional women access to Phexxi® (lactic acid, citric acid, potassium bitartrate) for the prevention of pregnancy.
SAN DIEGO, May 21, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock and accompanying two-year warrants to purchase an aggregate of up to 50 million shares of common stock. In addition, Evofem granted the underwriter a 30-day option to purchase up to an additional 7.5 million shares of its common stock and/or accompanying warrants to purchase an aggregate of up to 7.5 million shares of its common stock, which the underwriter has partially exercised for warrants to purchase an aggregate of up to 7.5 million shares of common stock. At closing, Evofem received net proceeds from the offering of approximately $46.6 million, after deducting underwriting discounts and commissions and estimated offering expenses. All of the securities in the offering were sold by Evofem.
Evofem has announced new data from the Phase III AMPOWER clinical trial of Phexxi (lactic acid, citric acid, and potassium bitartrate), which revealed that women who enrolled in the AMPOWER trial had fewer urinary tract infections (UTIs) compared to the general population.
SAN DIEGO, Jan. 19, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced strong preliminary results for the fourth quarter of 2021, including record growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate).
Poly(lactic acid), or PLA, is a biodegradable, biocompatible polyester ncommonly used in many medical, pharmaceutical, and biotechnology nproducts. The molecular weight of PLA can be tailored to impart various ndegradation kinetics and subsequent release profiles. The ability to nmake microcapsules with a thin PLA shell, however, is non-existent in nthe controlled release space. Here, using a proprietary Strat?mTM ntechnology, we have created 50 ?m capsules with an aqueous core and thinnPLA shell. The microcapsules have implications for encapsulating nwater-soluble molecules such as peptides and proteins, which can be nreleased with a discrete pulse, or slow ramp in release rate.
A newly developed 3D-printable tissue scaffold is designed to break down in the body once it has served its medical purpose. The 4Degra biodegradable and customizable biomaterial could provide support for healing across tissue types, including soft tissue post-surgery or for support in orthopedics, and it could eliminate the potential complications with long-term devices or removal.